316-330 of 894
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Charles Turck, PharmD, BCPS, BCCCP
Matthew Lunning, DO, FACP
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
- advertisement
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Project Oncology®Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Samhitha Gundakaram, MBBS
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Jorge Nieva, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
- advertisement
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Jorge Nieva, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
George Laliotis, MD, MPH, MHA
